Select a medication above to begin.
dextroamphetamine/ amphetamine
generic
Black Box Warnings .
Abuse, Misuse, and Addiction
CNS stimulants have high potential for abuse and misuse, can lead to substance use disorder, incl. addiction; misuse and abuse can result in overdose and death, risk incr. w/ higher doses or unapproved admin. methods; assess risk for abuse, misuse, and addiction before prescribing and throughout tx; educate pts and families about risks and proper drug storage and disposal; monitor frequently for s/sx of abuse, misuse, and addiction during tx
Adult Dosing .
Dosage forms: ER CAP: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg; TAB: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg
Special Note
- [formulation clarification]
- Info: dextroamphetamine/amphetamine ER cap not interchangeable w/ Mydayis, do not substitute on a mg to mg basis
ADHD
- [immediate-release form]
- Dose: 5-40 mg/day PO divided qd-tid; Start: 5 mg PO qam or bid, may incr. by 5 mg/day qwk; Info: duration 5-8h; give divided doses at 4-6h intervals; doses >40 mg/day rarely more effective
- [extended-release form]
- Dose: 20 mg ER PO qam; Start: 20 mg ER PO qam, may incr. by 10 mg/day qwk; Max: 60 mg/day ER; Info: duration 10-12h; may convert from IR to ER at same total daily dose qam; doses >20 mg/day rarely more effective; may open ER cap, but do not crush/chew contents
narcolepsy
- [5-60 mg/day PO divided qd-tid]
- Start: 10 mg PO qam, may incr. by 10 mg/day qwk; Info: give divided doses at 4-6h intervals
renal dosing
- [immediate-release form]
- renal impairment: not defined
- HD/PD: not defined
- [extended-release form]
- eGFR 15-29: 15 mg qam; eGFR <15: avoid use
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: ER CAP: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg; TAB: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg
Special Note
- [formulation clarification]
- Info: dextroamphetamine/amphetamine ER cap not interchangeable w/ Mydayis, do not substitute on a mg to mg basis
ADHD
- [immediate-release form, 3-5 yo]
- Dose: 2.5-40 mg/day PO divided qd-tid; Start: 2.5 mg PO qam, may incr. by 2.5 mg/day qwk; Info: duration 5-8h; give divided doses at 4-6h intervals; doses >40 mg/day rarely more effective
- [immediate-release form, 6 yo and older]
- Dose: 5-40 mg/day PO divided qd-tid; Start: 5 mg PO qam or bid, may incr. by 5 mg/day qwk; Info: duration 5-8h; give divided doses at 4-6h intervals; doses >40 mg/day rarely more effective
- [extended-release form, 6-12 yo]
- Dose: 10 mg ER PO qam; Start: 5-10 mg ER PO qam, may incr. by 5-10 mg/day qwk; Max: 30 mg/day ER; Info: duration 10-12h; may convert from IR to ER at same total daily dose qam; may open ER cap, but do not crush/chew contents
- [extended-release form, 13-17 yo]
- Dose: 10-20 mg ER PO qam; Start: 10 mg ER PO qam, may incr. by 10 mg/day qwk; Max: 40 mg/day ER; Info: duration 10-12h; may convert from IR to ER at same total daily dose qam; doses >20 mg/day rarely more effective; may open ER cap, but do not crush/chew contents
narcolepsy
- [6-11 yo]
- Dose: 5-60 mg/day PO divided qd-tid; Start: 5 mg PO qam, may incr. by 5 mg/day qwk; Info: give divided doses at 4-6h intervals
- [12 yo and older]
- Dose: 5-60 mg/day PO divided qd-tid; Start: 10 mg PO qam, may incr. by 10 mg/day qwk; Info: give divided doses at 4-6h intervals
renal dosing
- [immediate-release form]
- renal impairment: not defined
- HD/PD: not defined
- [extended-release form]
- eGFR 15-29: 5 mg qam in pts 6-17 yo, max 20 mg/day in pts 6-12 yo; eGFR <15: avoid use
- HD/PD: not defined
hepatic dosing
- [not defined]